Analytical Data
-
Gene name
CPA2
- Application
-
Alternative Names
CPA2；Carboxypeptidase A2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P48052
-
Expression Region
115-419aa
-
AA Sequence
SGNFNF GAYHTLEEIS QEMDNLVAEH PGLVSKVNIG SSFENRPMNV LKFSTGGDKP AIWLDAGIHA REWVTQATAL WTANKIVSDY GKDPSITSIL DALDIFLLPV TNPDGYVFSQ TKNRMWRKTR SKVSGSLCVG VDPNRNWDAG FGGPGASSNP CSDSYHGPSA NSEVEVKSIV DFIKSHGKVK AFITLHSYSQ LLMFPYGYKC TKLDDFDELS EVAQKAAQSL RSLHGTKYKV GPICSVIYQA SGGSIDWSYD YGIKYSFAFE LRDTGRYGFL LPARQILPTA EETWLGLKAI MEHVRDHPY
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CPA2, or Cysteine Proteinase A2, is a novel protein that has gained attention in the field of molecular biology and biotechnology due to its significant role in various biological processes. Research into CPA2 has been driven by its potential applications in therapeutic development, particularly in targeting specific diseases such as cancer and metabolic disorders. Studies have indicated that CPA2 is involved in the regulation of protein turnover and has unique enzymatic activities that could be harnessed for biotechnological applications. The reconstitution of CPA2 as a recombinant protein allows for a detailed investigation of its structural and functional properties, paving the way for the development of enzyme inhibitors or activators. Furthermore, understanding the mechanisms by which CPA2 functions at the molecular level can provide insights into its role in cellular physiology and its potential as a biomarker for disease diagnosis. Overall, CPA2 represents a promising target for pharmaceutical research and therapeutic innovation, making it a focal point of ongoing studies in protein engineering and drug development.
